#Pharmacovigilance #DrugSafety #Pharmacology #ClinicalResearch #PatientSafety #DrugInteractions #Cardiotoxicity #QTProlongation #TorsadesDePointes #CYP3A4 #DrugDevelopment #MedicationSafety #ClinicalPharmacology #Healthcare #MedicalEducation To view or add a comment, sign in CDSCO New Drug Therapy Approval | July 2026 India continues to strengthen its therapeutic landscape with another important drug approval
The way forward for understanding metabolic risk As noted in our Life Science Report, newer obesity medications have shown unprecedented weight loss outcomes, offering the potential to reduce obesity-related mortality and morbidity risk
All GLP-1R agonists have the same mode of function but differ in half-life duration
2018KF02) Publishers Note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Neurochemical Research 2008
phase 2 trial data show significant weight reduction, but it remains unapproved by the MHRA or EMA
